Drugs

, Volume 63, Issue 5, pp 493–512

Intramuscular Preparations of Antipsychotics

Uses and Relevance in Clinical Practice
  • A. Carlo Altamura
  • Francesca Sassella
  • Annalisa Santini
  • Clauno Montresor
  • Sara Fumagalli
  • Emanuela Mundo
Review Article

Abstract

Intramuscular formulations of antipsychotics can be sub-divided into two groups on the basis of their pharmacokinetic features: short-acting preparations and long-acting or depot preparations. Short-acting intramuscular formulations are used to manage acute psychotic episodes. On the other hand, long-acting compounds, also called ‘depot’, are administered as antipsychotic maintenance treatment to ensure compliance and to eliminate bioavailability problems related to absorption and first pass metabolism.

Adverse effects of antipsychotics have been studied with particular respect to oral versus short- and long-acting intramuscular formulations of the different compounds. For short-term intramuscular preparations the main risk with classical compounds are hypotension and extrapyramidal side effects (EPS). Data on the incidence of EPS with depot formulations are controversial: some studies point out that the incidence of EPS is significantly higher in patients receiving depot preparations, whereas others show no difference between oral and depot antipsychotics.

Studies on the strategies for switching patients from oral to depot treatment suggest that this procedure is reasonably well tolerated, so that in clinical practice depot antipsychotic therapy is usually begun while the oral treatment is still being administered, with gradual tapering of the oral dose.

Efficacy, pharmacodynamics and clinical pharmacokinetics of haloperidol decanoate, fluphenazine enanthate and decanoate, clopenthixol decanoate, zuclopenthixol decanoate and acutard, flupenthixol decanoate, perphenazine enanthate, pipothiazine palmitate and undecylenate, and fluspirilene are reviewed. In addition, the intramuscular preparations of atypical antipsychotics and clinical uses are reviewed. Olanzapine and ziprasidone are available only as short-acting preparations, while risperidone is to date the only novel antipsychotic available as depot formulation.

To date, acutely ill, agitated psychotic patients have been treated with high parenteral doses of typical antipsychotics, which often cause serious EPS, especially dystonic reactions. Intramuscular formulations of novel antipsychotics (olanzapine and ziprasidone), which appear to have a better tolerability profile than typical compounds, showed an equivalent efficacy to parenteral typical agents in the acute treatment of psychoses. However, parenteral or depot formulations of atypical antipsychotics are not yet widely available.

References

  1. 1.
    Madhusoodanan S, Brenner R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999; 12(2): 135–50CrossRefGoogle Scholar
  2. 2.
    Thomas CS, Lewis S. Which atypical antipsychotic? Br J Psychiatry 1998; 172: 106–9PubMedCrossRefGoogle Scholar
  3. 3.
    Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int J Psychopharmacol 1995; 10: 207–13CrossRefGoogle Scholar
  4. 4.
    Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000 Dec 2; 321(7273): 1371–6PubMedCrossRefGoogle Scholar
  5. 5.
    Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290–9PubMedCrossRefGoogle Scholar
  6. 6.
    Barnes TRE, Curson DA. Long-term depot antipsychotics a risk-benefit assessment. Drug Saf 1994; 10(6): 464–79PubMedCrossRefGoogle Scholar
  7. 7.
    Ayd FJ. The depot fluphenazines: a reappraisal after 10 years clinical experience. Am J Psychiatry 1975; 132: 491–500PubMedGoogle Scholar
  8. 8.
    Johnson DAW. Practical considerations in the use of depot neuroleptics for the treatment of schizophrenia. Br J Hosp Med 1977; 17: 546–58PubMedGoogle Scholar
  9. 9.
    Altamura AC, Tacchini GL, Maes M. Haloperidol plasma ‘Threshold’ levels for relapse prevention in schizophrenia: a study with haloperidol decanoate. Eur Neuropsychopharmacol 1995; 5(S): 55–8PubMedCrossRefGoogle Scholar
  10. 10.
    Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001; 179: 300–7PubMedCrossRefGoogle Scholar
  11. 11.
    Pereira S, Pinto R. A survey of the attitudes of chronic psychiatric patients living in the community toward their medication. Acta Psychiatr Scand 1997; 95: 464–8PubMedCrossRefGoogle Scholar
  12. 12.
    Davis JM, Leor M, Watanabe MD, et al. Depot antipsychotic drugs, place in therapy. Drugs 1994; 47(5): 741–73PubMedCrossRefGoogle Scholar
  13. 13.
    Altamura AC, Whelpton R, Curry SH. Animal model for investigation of fluphenazine kinetics after administration of long-acting esters. Biopharm Drug Dispos 1979; 1: 65–72PubMedCrossRefGoogle Scholar
  14. 14.
    Curry SH, Altamura AC, Montgomery S. Unwanted effects of fluphenazine enanthate and decanoate. Lancet 1979; I: 331–3CrossRefGoogle Scholar
  15. 15.
    Milton GV, Jann MW. Emergency treatment of psychotic symptoms: pharmacokinetic considerations for antipsychotic drugs. Clin Pharmacokinet 1995; 28(6): 494–504PubMedCrossRefGoogle Scholar
  16. 16.
    Tune L. The role of antipsychotics in treating delirium. Curr Psychiatry Rep 2002; 4(3): 209–12PubMedCrossRefGoogle Scholar
  17. 17.
    Altamura AC. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they ‘stabilizer’ rather than typical compounds? Int Clin Psychopharmacol 1996; 11: 1–3CrossRefGoogle Scholar
  18. 18.
    Jones B, Taylor CC, Meehan K. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms. J Clin Psychiatry 2001; 62 Suppl. 2: 22–4PubMedGoogle Scholar
  19. 19.
    Clinton JE, Sterner S, Stelmachers Z, et al. Haloperidol for sedation of disruptive emergency patients. Ann Emerg Med 1987; 16(3): 319–22PubMedCrossRefGoogle Scholar
  20. 20.
    Schaffer CB, Shahid A, Javaid JI, et al. Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol 1982; 2: 274–7PubMedCrossRefGoogle Scholar
  21. 21.
    Dubin WR, Wasman HM, Weiss KJ, et al. Rapid tranquilization: the efficacy of oral concentrate. J Clin Psychiatry 1985; 46: 475–8PubMedGoogle Scholar
  22. 22.
    Hughes DH. Acute polypharmacological management of the aggressive psychotic patient. Psychiatr Serv 1999; 50: 1135–7PubMedGoogle Scholar
  23. 23.
    Garza-Trevino ES, Hollister LE, Overall JE, et al. Efficacy of combinations of intramuscular antipsychotics and sedative-hypnotics for control of psychotic agitation. Am J Psychiatry 1989; 146: 1598–601PubMedGoogle Scholar
  24. 24.
    Hyman SE. Acute psychoses and catatonia. In: Hyman SE, Tesar GE, editors. Manual of psychiatric emergencies. 3rd ed. Boston (MA): Little, Brown, 1994: 143–57Google Scholar
  25. 25.
    Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry 2001; 9(3): 89–104PubMedCrossRefGoogle Scholar
  26. 26.
    Lazarus A, Dubin WR, Jaffe R. Rapid tranquilization with neuroleptic drugs. Clin Neuropharmacol 1989; 12: 303–11PubMedCrossRefGoogle Scholar
  27. 27.
    Ericksen SE, Hurt SW, Chang S, et al. Haloperidol dose, plasma levels, and clinical response: a double blind study. Psychopharmacol Bull 1978; 14: 15–6PubMedGoogle Scholar
  28. 28.
    Donlon PT, Meadow A, Tupin JP, et al. High versus standard dose of fluphenazine HCL in acute schizophrenia. J Clin Psychiatry 1978; 39: 800–4PubMedGoogle Scholar
  29. 29.
    Escobar JI, Barron A, Kiriakos R. A controlled study of neuroleptisation with fluphenazine hydrochloride injections. J Clin Psychopharmacol 1983; 3: 359–62PubMedCrossRefGoogle Scholar
  30. 30.
    Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuro-psychopharmacol 1998; 8: 55–66CrossRefGoogle Scholar
  31. 31.
    Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9: 17–20PubMedCrossRefGoogle Scholar
  32. 32.
    Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry 2001; 62(3): 153–7PubMedCrossRefGoogle Scholar
  33. 33.
    Dencker SJ, Axelsson R. Optimising the use of depot antipsychotics. CNS Drugs 1996; 6(5): 367–81CrossRefGoogle Scholar
  34. 34.
    Falloon I, Watt DC, Shepherd M. A comparative control trial of pimozide and fluphenazine decanoate in the continuation therapy of schizophrenia. Psychol Med 1978; 8: 59–70PubMedCrossRefGoogle Scholar
  35. 35.
    Quitkin F, Rifkin A, Kane JM, et al. Long-acting oral vs injectable antipsychotic drugs in schizophrenics. Arch Gen Psychiatry 1978; 35: 889–92PubMedCrossRefGoogle Scholar
  36. 36.
    Weiden P, Rapkin B, Zygmut A, et al. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatr Serv 1995; 46(10): 1049–54PubMedGoogle Scholar
  37. 37.
    Curry SH. Metabolism and kinetics of chloropromazine in relation to effect. In: Sedvall G, Uvnas B, Zolterman R, editors. Antipsychotic drugs: pharmacokinetics and pharmacodynamics. Oxford: Pergamon Press, 1976: 343–52Google Scholar
  38. 38.
    Altamura AC. A multidimensional (pharmacokinetic and clinical-biological) approach to the neuroleptic response in schizophrenia. Schizophr Res 1992; 8: 187–98CrossRefGoogle Scholar
  39. 39.
    Roy A. Suicide in chronic schizophrenia. Br J Psychiatry 1982; 141: 171–7PubMedCrossRefGoogle Scholar
  40. 40.
    Wilkinson D. The suicide rate in schizophrenia. Br J Psychiatry 1982; 140: 138–41PubMedCrossRefGoogle Scholar
  41. 41.
    Altamura AC, Bassetti R, Bignotti S, et al. Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 2003; 60(1): 47–55PubMedCrossRefGoogle Scholar
  42. 42.
    Schooler NR. Treatment of schizophrenia: maintenance strategies and pharmacologic tactics. In: Albert M, editor. Controversies in schizophrenia. New York: Guilford Press, 1985: 380Google Scholar
  43. 43.
    Soni SD, Sampath G, Shah A, et al. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. Acta Psychiatr Scand 1992; 85(5): 354–9PubMedCrossRefGoogle Scholar
  44. 44.
    Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medication in preventing schizophrenic recidivism. J Clin Psychiatry 1987; 48(3): 94–7PubMedGoogle Scholar
  45. 45.
    Johnson DA. Oral versus depot medication in schizophrenia. Acta Psychiatr Scand Suppl 1981; 291: 56–64PubMedCrossRefGoogle Scholar
  46. 46.
    Kane JM. Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 65–71PubMedGoogle Scholar
  47. 47.
    Altamura AC, Mauri M, Mantero M, et al. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand 1987; 76: 702–6PubMedCrossRefGoogle Scholar
  48. 48.
    Battaglia J, Moss S, Rush J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 1997; 15: 335–40PubMedCrossRefGoogle Scholar
  49. 49.
    Neborsky R, Janowsky D, Munson E, et al. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol: behavioral considerations. Arch Gen Psychiatry 1981; 38: 195–9PubMedCrossRefGoogle Scholar
  50. 50.
    Salzman C, Solomon D, Miyawaki E, et al. Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 1991; 52: 177–80PubMedGoogle Scholar
  51. 51.
    Chien CP, Cole JO. Depot phenotiazine treatment in acute psychosis: a sequential comparative clinical study. Am J Psychiatry 1973; 130: 13–8PubMedGoogle Scholar
  52. 52.
    Del Giudice J, Clark WG, Gocka EF. Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 1975; 16: 32–6PubMedGoogle Scholar
  53. 53.
    Kesseler KA, Waletzky JP. Clinical use of the antipsychotics. Am J Psychiatry 1981; 138: 202–9Google Scholar
  54. 54.
    Gelenberg AJ, Doller JC, Schooler NR, et al. Acute extra-pyramidal reactions with fluphenazine hydrochloride and fluphenazine decanoate. Am J Psychiatry 1979; 136: 217–9PubMedGoogle Scholar
  55. 55.
    Vasavan NP, Suranyi-Cadotte B, Schwartz G, et al. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence. J Clin Psychopharmacol 1986; 6(l): 30S–7SCrossRefGoogle Scholar
  56. 56.
    Burch EA, Ayd FJ. Depot pipotiazine 1970–1982: a review. J Clin Psychiatry 1983; 44: 242–7PubMedGoogle Scholar
  57. 57.
    Pakes GE. Haloperidol: profile of side-effects. In: Johnson P, editor. Haloperidol decanoate and the treatment of chronic schizophrenia. New York: Adis Press, 1982: 58–63Google Scholar
  58. 58.
    Youssef HA. Haloperidol decanoate in place of multiple drug therapy in chronic schizophrenic patients. Acta Therapeutica 1983; 9: 215–25Google Scholar
  59. 59.
    Knudsen P, Hansen LB, Auken G, et al. Perphenazine decanoate vs perphenazine enanthate: efficacy and side effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatr Scand Suppl 1985; 322: 15–28PubMedCrossRefGoogle Scholar
  60. 60.
    Bransgrove LL, Kelly MW. Movement disorders in patients treated with long-acting injectable antipsychotic drugs. Am J Hosp Pharm 1994 Apr 1; 51(7): 895–9PubMedGoogle Scholar
  61. 61.
    Altamura AC, Curry SH, Montgomery S, et al. Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentration in schizophrenic patients. Psychopharmacology (Berl) 1985; 87(1): 30–3CrossRefGoogle Scholar
  62. 62.
    Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992 Dec; 53: 426–33PubMedGoogle Scholar
  63. 63.
    Kaneko S, Edwards JG, Goldie A, et al. Effect of haloperidol decanoate on the cardiovascular system. Jpn J Psychiatry Neurol 1991; 45(1): 73–7PubMedGoogle Scholar
  64. 64.
    Starmark JE, Forsman A, Wahlstrom J. Abscesses following prolonged intramuscular administration of perphenazine enanthate. Acta Psychiatr Scand 1980; 62: 154–7PubMedCrossRefGoogle Scholar
  65. 65.
    British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain: London, 1993Google Scholar
  66. 66.
    Beresford R, Ward A. Haloperidol decanoate: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychoses. Drugs 1987; 33: 31–49PubMedCrossRefGoogle Scholar
  67. 67.
    Wei FC, Jann MW, Lin HN, et al. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy. J Clin Psychiatry 1996; 57(7): 298–302PubMedGoogle Scholar
  68. 68.
    Ereshefsky L, Toney G, Saklad SR, et al. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry 1993; 44(12): 1155–61PubMedGoogle Scholar
  69. 69.
    Altamura AC, Colacurcio F, Mauri MC, et al. Haloperidol decanoate in chronic schizophrenia: a follow-up study of 12 months with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 163–70PubMedCrossRefGoogle Scholar
  70. 70.
    Altamura AC, Vita A, Giobbio GM, et al. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. Int Clin Psychopharmacol 1994; 9(1): 3–7PubMedCrossRefGoogle Scholar
  71. 71.
    Kane JM, Davis JM, Schooler NR, et al. A one-year comparison of four dosages of haloperidol decanoate. Psychopharmacol Bull 1994; 30: 107, 1994Google Scholar
  72. 72.
    Zonda T, Kovari E. Use of haloperidol decanoate in psychiatric diseases. Ther Hung 1992; 40(2): 64–8PubMedGoogle Scholar
  73. 73.
    Froemming JS, Lam YW, Jann MW, et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17(6): 396–423PubMedCrossRefGoogle Scholar
  74. 74.
    Deberdt R, Elens P, Berghmans W, et al. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy: efficacy, dosage schedule and plasma levels. An open multicenter study. Acta Psychiatr Scand 1980; 62(4): 356–63CrossRefGoogle Scholar
  75. 75.
    Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159(4): 554–60PubMedCrossRefGoogle Scholar
  76. 76.
    Gelders YG, Reyntijens AJ, Ash CW, et al. 12-month study of haloperidol decanoate in chronic schizophrenic patients. Int Pharmacopsychiatry 1982; 17(4): 247–54PubMedGoogle Scholar
  77. 77.
    Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia: a long-term double-blind cross-over comparison. Acta Psychiatr Scand 1986; 74(3): 255–62PubMedCrossRefGoogle Scholar
  78. 78.
    McKane JP, Robinson AD, Wiles DH, et al. Haloperidol decanoate vs fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. Br J Psychiatry 1987; 151: 333–6PubMedCrossRefGoogle Scholar
  79. 79.
    Youssef HA. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Clin Neuropharmacol 1991; 14 Suppl. 2: S16–21PubMedGoogle Scholar
  80. 80.
    Quraishi S, David A. Depot haloperidol decanoate for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001717Google Scholar
  81. 81.
    Brook S, Lucey JV, Gunn K. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. J Clin Psychiatry 2000; 61: 933–41PubMedCrossRefGoogle Scholar
  82. 82.
    Wright P, Birkett MA, David S, et al. Double-blind, placebo controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry 2001; 158: 1149–51PubMedCrossRefGoogle Scholar
  83. 83.
    Ulrich S, Neuhof S, Braun V, et al. Reduced haloperidol does not interfere with antipsychotic activity of haloperidol in the treatment of acute schizophrenia. Int Clin Psychopharmacol 1999; 14: 219–28PubMedCrossRefGoogle Scholar
  84. 84.
    Altamura AC, Bareggi SR. Comment on ‘Reduced haloperidol does not interfere with antipsychotic activity of haloperidol in the treatment of acute schizophrenia’. Int Clin Psychopharmacol2000; 15: 303–4PubMedCrossRefGoogle Scholar
  85. 85.
    Bucci L, Fuchs M, Simeon J, et al. Depot fluphenazine in the treatment of psychosis in a community mental health clinic. Dis Nerv Syst 1970; 31: 28–31PubMedGoogle Scholar
  86. 86.
    Caffey EM, Diamond LS, Frank TV, et al. Discontinuation or reduction of chemotherapy in chronic scizophrenics. J Chronic Dis 1964; 17: 347–58PubMedCrossRefGoogle Scholar
  87. 87.
    Carpenter Jr WT, Buchanan RW, Kirkpatrick B, et al. Comparative effectiveness of fluphenazine decanoate injections every 2 weeks versus every 6 weeks. Am J Psychiatry 1999 Mar; 156(3): 412–8PubMedGoogle Scholar
  88. 88.
    Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two year outcome. Arch Gen Psychiatry 1987; 44: 518–21PubMedCrossRefGoogle Scholar
  89. 89.
    Chouinard G, Annable L, Campbell W. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharmacol 1989 Aug; 9(4): 247–53PubMedCrossRefGoogle Scholar
  90. 90.
    Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull 1988; 24: 112–7PubMedGoogle Scholar
  91. 91.
    Ahlfors UG, Dencker SJ, Gravem A, et al. Clopenthixol decanoate and perphenazine enantathe in schizophrenic patients: a double-blind Nordic multicentre trial. Acta Psychiatr Scand Suppl 1980; 279: 77–91PubMedGoogle Scholar
  92. 92.
    Martyns-Yellow IS. The decanoate of flupenthixol and clopenthixol in the treatment of chronic schizophrenia in-patients: implications for community psychiatry. West Afr J Med 1993; 12(2): 110–3Google Scholar
  93. 93.
    Borsetti G, Rocco P, Spilimbergo PG, et al. Long-term treatment of chronic schizophrenics with clopenthixol decanoate. Pharmatherapeutica 1984; 4(1): 53–6PubMedGoogle Scholar
  94. 94.
    Carney MW. A 5-year follow-up study of chronic schizophrenics treated with clopenthixol decanoate. Pharmatherapeutica 1984; 4(1): 57–63PubMedGoogle Scholar
  95. 95.
    Aaes-Jorgensen T. Pharmacokinetics of three different injectable zuclopenthixol preparations. Prog Neuropsychopharmacol Biol Psychiatry 1989; 13: 77–85PubMedCrossRefGoogle Scholar
  96. 96.
    Sieberns S, Spechtmeyer H. cis (Z)-Clopenthixol decanoate: a new depot neuroleptic. Int Pharmacopsychiatry 1982; 17(3): 170–84PubMedGoogle Scholar
  97. 97.
    Lambert PA, Chabannes JP. A new injectable delayed-action neuroleptic with sedative and antipsychotic action: cis-(Z)-clopenthixol decanoate: clinical trials. Encephale 1984; 10(2): 83–91PubMedGoogle Scholar
  98. 98.
    Solgaard T, Kistrup K, Aaes-Jorgensen T, et al. Zuclopenthixol decanoate in maintenance treatment of schizophrenic outpatients: minimum effective dose and corresponding serum levels. Pharmacopsychiatry 1994 May; 27(3): 119–23PubMedCrossRefGoogle Scholar
  99. 99.
    Kasi HA. An open clinical trial with the long-acting neuroleptic zuclopenthixol decanoate in the maintenance of schizophrenia. Pharmatherapeutica 1986; 4(9): 555–60Google Scholar
  100. 100.
    Bttig D. Use of clopixol acutard 50 and 100mg (zuclopenthixol acetate) as a therapeutic drug in crisis at the Cery psychiatric hospital. Schweiz Arch Neurol Psychiatr 1988; 139(5): 35–47PubMedGoogle Scholar
  101. 101.
    Lowert AC, Rasmussen EM, Holm R, et al. Acute psychotic disorders treated with 5% zuclopenthixol acetate in ‘Viscoleo’ (Cisordinol-Acutard), a global assessment of the clinical effect: an open multi-centre study. Pharmatherapeutica 1989; 5(6): 380–6PubMedGoogle Scholar
  102. 102.
    Reynolds JEF. Anxiolytic sedatives, hypnotics and neuroleptics. In: Reynolds JEF, editor. Martindale: the extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993: 364–623Google Scholar
  103. 103.
    Budde G. Efficacy and tolerability of flupenthixol decanoate in the treatment of depression and psychosomatic disorders: a multicenter trial in general practice. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16(5): 677–89PubMedCrossRefGoogle Scholar
  104. 104.
    Maragakis BP. A double-blind comparison of oral amitriptyline and low-dose intramuscular flupenthixol decanoate in depressive illness. Curr Med Res Opin 1990; 12(1): 51–7PubMedCrossRefGoogle Scholar
  105. 105.
    Poldinger W, Sieberns S. Depression-inducing and antidepressive effects of neuroleptics: experiences with flupenthixol and flupenthixol decanoate. Neuropsychobiol 1983; 10(2–3): 131–6Google Scholar
  106. 106.
    Quraishi S, David A. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001470Google Scholar
  107. 107.
    Pach J, Finkbeiner T, Glaser T, et al. Positive and negative symptoms in chronic schizophrenic patients under maintenance therapy with flupenthixol decanoate for a twelve month period. Fortschr Neurol Psychiatr 1998; 66(10): 442–9PubMedCrossRefGoogle Scholar
  108. 108.
    Kong DS, Yeo SH. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica 1989; 5(6): 371–9PubMedGoogle Scholar
  109. 109.
    Singh AN. Therapeutic efficacy of flupenthixol decanoate in schizoaffective disorder: a clinical evaluation. J Int Med Res1984; 12(1): 17–22PubMedGoogle Scholar
  110. 110.
    Knudsen P, Hansen LB, Larsen NE. Perphenazine decanoate in sesame oil vs perphenazine enanthate in sesame oil: a comparative study of pharmacokinetic properties and some clinical implications. Acta Psychiatr Scand Suppl 1985; 322: 11–4PubMedCrossRefGoogle Scholar
  111. 111.
    Quraishi S, David A. Depot perphenazine decanoate and enanthate for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001717Google Scholar
  112. 112.
    Tuninger E, Levander S. Large variations of plasma levels during maintenance treatment with depot neuroleptics. Br J Psychiatry 1996; 169(5): 618–21PubMedCrossRefGoogle Scholar
  113. 113.
    Tegeler J, Floru L. A comparative study of the longacting neuroleptics perphenazin-enanthate and fluspirilene. Pharmakopsychiatr Neuropsychopharmakol 1979 Sep; 12(5): 357–65PubMedGoogle Scholar
  114. 114.
    Dencker SJ, Gios I, Martensson E, et al. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology (Berl) 1994 Feb; 114(1): 24–30CrossRefGoogle Scholar
  115. 115.
    Imlah NW, Murphy KP. Ten-year follow-up of schizophrenic patients on pipothiazine palmitate. Curr Med Res Opin 1985; 9(7): 449–53PubMedCrossRefGoogle Scholar
  116. 116.
    Woggon B, Dick P, Fleischhauer HJ, et al. Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate: results of a multicenter double-blind trial. Int Pharmacopsychiatry 1977; 12(4): 193–209PubMedGoogle Scholar
  117. 117.
    Chouinard G, Annable L, Kropsky M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. J Clin Pharmacol 1978 Feb–Mar; 18(2–3): 148–54PubMedGoogle Scholar
  118. 118.
    Leong OK, Wong KE, Tay WK, et al. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia. Singapore Med J 1989; 30(5): 436–40PubMedGoogle Scholar
  119. 119.
    Bechelli LP, Navas-Filho F. Short-term double-blind trial of pipothiazine palmitate and haloperidol in the acute phase of schizophrenia. Encephale 1986; 12(3): 121–5PubMedGoogle Scholar
  120. 120.
    Steinert J, Neder A, Erba E, et al. A comparative trial of depot pipothiazine. J Int Med Res 1986; 14(2): 72–7PubMedGoogle Scholar
  121. 121.
    Quraishi S, David A. Depot pipothiazine palmitate and undeclynate for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001720Google Scholar
  122. 122.
    Chouinard G, Annable L, Steinberg S. A controlled clinical trial of fluspirilene, a long acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 1986; 6: 21–6PubMedCrossRefGoogle Scholar
  123. 123.
    Kanowski S, Paur R. Experience with fluspirilene in gerontopsychiatry. Pharmakopsychiatr Neuropsychopharmakol 1980 May; 13(3): 137–43PubMedGoogle Scholar
  124. 124.
    Tanghe A. A retrospective evaluation of long-term fluspirilene (IMAP) treatment. Acta Psychiatr Belg 1976 May; 76(3): 480–90PubMedGoogle Scholar
  125. 125.
    Soni SD. Fluspirilene in the treatment of non-hospitalized schizophrenic patients. Curr Med Res Opin 1977; 4(9): 645–9PubMedCrossRefGoogle Scholar
  126. 126.
    Russel N, Landmark J, Merskey H, et al. A double blind comparison of fluspirilene and fluphenazine decanoate in schizophrenia. Can J Psychiatry 1982; 27(7): 593–6Google Scholar
  127. 127.
    Quraishi S, David A. Depot fluspirilene for schizophrenia. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Update software, 2000. CD001718Google Scholar
  128. 128.
    Carpenter Jr WT, Zito JM, Vitrai J, et al. Hypothesis testing: is clozapine’s superior efficacy dependent on moderate D2 receptor occupancy? Biol Psychiatry 1998 Jan 15; 43(2): 79–83PubMedCrossRefGoogle Scholar
  129. 129.
    Meehan K, Zhang F, David S, et al. A Double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001; 21(4): 389–97PubMedCrossRefGoogle Scholar
  130. 130.
    Wright P, Jewell H, Mitchell M, et al. A preliminary study of the safety, efficacy and pharmacokinetics of intramuscular olanzapine in patients with acute nonorganic psychosis [abstract]. Schizophr Res 1999; 36: 318Google Scholar
  131. 131.
    Wright P, Kiesler G, Mitchell M, et al. Safety and efficacy of intramuscular olanzapine in patients with acute non organic psychosis [abstract]. Schizophr Res 1999; 36: 318Google Scholar
  132. 132.
    Eerdekens M, Rasmussen M, Vermeulen A, et al. Kinetics and safety of a novel risperidone depot formulation [abstract]. Int J Neuropsychopharmacol 2000; 3 Suppl. 1: S135Google Scholar
  133. 133.
    Gefvert O, Nyberg S, Persson P, et al. Pharmacokinetics, D2 receptor occupancy, and clinical effects of a long-acting injectable formulation of risperidone in patients with schizophrenia [abstract]. Biol Psychiatry 2001; 49 Suppl. 8: 117SGoogle Scholar
  134. 134.
    Kay SR, Opler LA, Lindenmayer JP. The positive and negative syndrome scale (PANSS): rationale and standardisation. Br J Psychiatry Suppl 1989; (7): 59–67Google Scholar
  135. 135.
    Eerdekens M, Fleischhacker WW, Xie Y, et al. Long-term safety of long-acting risperidone microspheres [abstract]. Schizophr Res 2002; 53 Suppl. 3: 174Google Scholar
  136. 136.
    Chue P, Eerdekens M, Augustyns I, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophr Res 2002; 53 Suppl. 3: 174–5Google Scholar
  137. 137.
    Miceli J, Wilner K, Folger C, et al. Pharmacokinetics of intramuscular ziprasidone in schizophrenic patients: population pharmacokinetic modelling [abstract]. Eur Neuropsychopharmacol 1998; 8: S215CrossRefGoogle Scholar
  138. 138.
    Brook S, Swift R, Harrigan EP. The tolerability and efficacy of intramuscular ziprasidone [abstract]. Eur Neuropsychopharmacol 1997; 7 Suppl. 2: 215CrossRefGoogle Scholar
  139. 139.
    Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular ziprasidone 20mg is effective in reducing agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacol 2001; 155: 128–34CrossRefGoogle Scholar
  140. 140.
    Lesem MD, Zajecka JM, Swift RH, et al. Intramuscular ziprasidone 2mg versus 10mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62: 12–8PubMedCrossRefGoogle Scholar
  141. 141.
    Dernovsek MZ, Prevolnik Rupel V, Rebolj M, et al. Quality of life and treatment costs in schizophrenic outpatients, treated with depot neuroleptics. Eur Psychiatry 2001; 16(8): 474–82PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • A. Carlo Altamura
    • 1
  • Francesca Sassella
    • 1
  • Annalisa Santini
    • 1
  • Clauno Montresor
    • 1
  • Sara Fumagalli
    • 1
  • Emanuela Mundo
    • 1
  1. 1.Department of Psychiatry, Department of Clinical Sciences ‘Luigi Sacco’University of MilanMilanItaly

Personalised recommendations